APO Research
Talk to an analyst

APO RESEARCH · REPORT

Critical Limb Ischemia Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Critical Limb Ischemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025191 pages

Choose your research edition.

Industry ResearchCritical Limb Ischemia Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Critical Limb Ischemia Drug Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Critical Limb Ischemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Critical Limb Ischemia Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Critical Limb Ischemia Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Critical Limb Ischemia Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Critical Limb Ischemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Critical Limb Ischemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Critical Limb Ischemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Critical Limb Ischemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Critical Limb Ischemia Drug include U.S. Stem Cell Inc, TikoMed AB, Symic Biomedical Inc, ReNeuron Group Plc, Pluristem Therapeutics Inc, Pharmicell Co Ltd, Nissan Chemical Industries Ltd, Neurofx Inc and Kasiak Research Pvt Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Critical Limb Ischemia Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Critical Limb Ischemia Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Critical Limb Ischemia Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Critical Limb Ischemia Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Critical Limb Ischemia Drug Segment by Company

U.S. Stem Cell Inc

TikoMed AB

Symic Biomedical Inc

ReNeuron Group Plc

Pluristem Therapeutics Inc

Pharmicell Co Ltd

Nissan Chemical Industries Ltd

Neurofx Inc

Kasiak Research Pvt Ltd

Hemostemix Inc

Cynata Therapeutics Ltd

Caladrius Biosciences Inc

BiogenCell Ltd

Critical Limb Ischemia Drug Segment by Type

NK-104 NP

NFx-101

JVS-100

HC-016

Others

Critical Limb Ischemia Drug Segment by Application

Hospital

Home Care

ASCs

Critical Limb Ischemia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Critical Limb Ischemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Critical Limb Ischemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Critical Limb Ischemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Critical Limb Ischemia Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Critical Limb Ischemia Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Critical Limb Ischemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Critical Limb Ischemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Critical Limb Ischemia Drug Industry Trends Table 2. Critical Limb Ischemia Drug Industry Drivers Table 3. Critical Limb Ischemia Drug Industry Opportunities and Challenges Table 4. Critical Limb Ischemia Drug Industry Restraints Table 5. Global Critical Limb Ischemia Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Critical Limb Ischemia Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Critical Limb Ischemia Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Critical Limb Ischemia Drug Sales Market Share by Manufacturers Table 9. Global Critical Limb Ischemia Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Critical Limb Ischemia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Critical Limb Ischemia Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Critical Limb Ischemia Drug Manufacturers, Product Type & Application Table 13. Global Critical Limb Ischemia Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Critical Limb Ischemia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of NK-104 NP Table 17. Major Manufacturers of NFx-101 Table 18. Major Manufacturers of JVS-100 Table 19. Major Manufacturers of HC-016 Table 20. Major Manufacturers of Others Table 21. Global Critical Limb Ischemia Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Critical Limb Ischemia Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Critical Limb Ischemia Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Critical Limb Ischemia Drug Sales Market Share by Type (2021-2026) Table 25. Global Critical Limb Ischemia Drug Sales Market Share by Type (2027-2032) Table 26. Global Critical Limb Ischemia Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Critical Limb Ischemia Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Critical Limb Ischemia Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Critical Limb Ischemia Drug Revenue Market Share by Type (2021-2026) Table 30. Global Critical Limb Ischemia Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Home Care Table 33. Major Manufacturers of ASCs Table 34. Global Critical Limb Ischemia Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Critical Limb Ischemia Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Critical Limb Ischemia Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Critical Limb Ischemia Drug Sales Market Share by Application (2021-2026) Table 38. Global Critical Limb Ischemia Drug Sales Market Share by Application (2027-2032) Table 39. Global Critical Limb Ischemia Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Critical Limb Ischemia Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Critical Limb Ischemia Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Critical Limb Ischemia Drug Revenue Market Share by Application (2021-2026) Table 43. Global Critical Limb Ischemia Drug Revenue Market Share by Application (2027-2032) Table 44. Global Critical Limb Ischemia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Critical Limb Ischemia Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Critical Limb Ischemia Drug Sales Market Share by Region (2021-2026) Table 47. Global Critical Limb Ischemia Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Critical Limb Ischemia Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Critical Limb Ischemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Critical Limb Ischemia Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Critical Limb Ischemia Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Critical Limb Ischemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Critical Limb Ischemia Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Critical Limb Ischemia Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Critical Limb Ischemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Critical Limb Ischemia Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Critical Limb Ischemia Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Critical Limb Ischemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Critical Limb Ischemia Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Critical Limb Ischemia Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Critical Limb Ischemia Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Critical Limb Ischemia Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Critical Limb Ischemia Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Critical Limb Ischemia Drug Revenue Market Share by Region (2021-2026) Table 65. Global Critical Limb Ischemia Drug Revenue Market Share by Region (2027-2032) Table 66. U.S. Stem Cell Inc Company Information Table 67. U.S. Stem Cell Inc Business Overview Table 68. U.S. Stem Cell Inc Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. U.S. Stem Cell Inc Critical Limb Ischemia Drug Product Portfolio Table 70. U.S. Stem Cell Inc Recent Development Table 71. TikoMed AB Company Information Table 72. TikoMed AB Business Overview Table 73. TikoMed AB Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. TikoMed AB Critical Limb Ischemia Drug Product Portfolio Table 75. TikoMed AB Recent Development Table 76. Symic Biomedical Inc Company Information Table 77. Symic Biomedical Inc Business Overview Table 78. Symic Biomedical Inc Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Symic Biomedical Inc Critical Limb Ischemia Drug Product Portfolio Table 80. Symic Biomedical Inc Recent Development Table 81. ReNeuron Group Plc Company Information Table 82. ReNeuron Group Plc Business Overview Table 83. ReNeuron Group Plc Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. ReNeuron Group Plc Critical Limb Ischemia Drug Product Portfolio Table 85. ReNeuron Group Plc Recent Development Table 86. Pluristem Therapeutics Inc Company Information Table 87. Pluristem Therapeutics Inc Business Overview Table 88. Pluristem Therapeutics Inc Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Pluristem Therapeutics Inc Critical Limb Ischemia Drug Product Portfolio Table 90. Pluristem Therapeutics Inc Recent Development Table 91. Pharmicell Co Ltd Company Information Table 92. Pharmicell Co Ltd Business Overview Table 93. Pharmicell Co Ltd Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Pharmicell Co Ltd Critical Limb Ischemia Drug Product Portfolio Table 95. Pharmicell Co Ltd Recent Development Table 96. Nissan Chemical Industries Ltd Company Information Table 97. Nissan Chemical Industries Ltd Business Overview Table 98. Nissan Chemical Industries Ltd Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Nissan Chemical Industries Ltd Critical Limb Ischemia Drug Product Portfolio Table 100. Nissan Chemical Industries Ltd Recent Development Table 101. Neurofx Inc Company Information Table 102. Neurofx Inc Business Overview Table 103. Neurofx Inc Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Neurofx Inc Critical Limb Ischemia Drug Product Portfolio Table 105. Neurofx Inc Recent Development Table 106. Kasiak Research Pvt Ltd Company Information Table 107. Kasiak Research Pvt Ltd Business Overview Table 108. Kasiak Research Pvt Ltd Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Kasiak Research Pvt Ltd Critical Limb Ischemia Drug Product Portfolio Table 110. Kasiak Research Pvt Ltd Recent Development Table 111. Hemostemix Inc Company Information Table 112. Hemostemix Inc Business Overview Table 113. Hemostemix Inc Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Hemostemix Inc Critical Limb Ischemia Drug Product Portfolio Table 115. Hemostemix Inc Recent Development Table 116. Cynata Therapeutics Ltd Company Information Table 117. Cynata Therapeutics Ltd Business Overview Table 118. Cynata Therapeutics Ltd Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Cynata Therapeutics Ltd Critical Limb Ischemia Drug Product Portfolio Table 120. Cynata Therapeutics Ltd Recent Development Table 121. Caladrius Biosciences Inc Company Information Table 122. Caladrius Biosciences Inc Business Overview Table 123. Caladrius Biosciences Inc Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Caladrius Biosciences Inc Critical Limb Ischemia Drug Product Portfolio Table 125. Caladrius Biosciences Inc Recent Development Table 126. BiogenCell Ltd Company Information Table 127. BiogenCell Ltd Business Overview Table 128. BiogenCell Ltd Critical Limb Ischemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. BiogenCell Ltd Critical Limb Ischemia Drug Product Portfolio Table 130. BiogenCell Ltd Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Critical Limb Ischemia Drug Distributors List Table 134. Critical Limb Ischemia Drug Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Critical Limb Ischemia Drug Product Image Figure 2. Global Critical Limb Ischemia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Critical Limb Ischemia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Critical Limb Ischemia Drug Sales (2021-2032) & (K Units) Figure 5. Global Critical Limb Ischemia Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Critical Limb Ischemia Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. NK-104 NP Image Figure 9. NFx-101 Image Figure 10. JVS-100 Image Figure 11. HC-016 Image Figure 12. Others Image Figure 13. Global Critical Limb Ischemia Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Critical Limb Ischemia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Critical Limb Ischemia Drug Sales Market Share by Type (2021-2032) Figure 16. Global Critical Limb Ischemia Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Critical Limb Ischemia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Critical Limb Ischemia Drug Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Home Care Image Figure 21. ASCs Image Figure 22. Global Critical Limb Ischemia Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Critical Limb Ischemia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Critical Limb Ischemia Drug Sales Market Share by Application (2021-2032) Figure 25. Global Critical Limb Ischemia Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Critical Limb Ischemia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Critical Limb Ischemia Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Critical Limb Ischemia Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Critical Limb Ischemia Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Critical Limb Ischemia Drug Sales Market Share by Country (2021-2032) Figure 42. China Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Critical Limb Ischemia Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Critical Limb Ischemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Critical Limb Ischemia Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Critical Limb Ischemia Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Critical Limb Ischemia Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Critical Limb Ischemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Critical Limb Ischemia Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Critical Limb Ischemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Critical Limb Ischemia Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Critical Limb Ischemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Critical Limb Ischemia Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Critical Limb Ischemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Critical Limb Ischemia Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Critical Limb Ischemia Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • NK-104 NP
  • NFx-101
  • JVS-100
  • HC-016
  • Others
Applications
  • Hospital
  • Home Care
  • ASCs
Companies covered
  • U.S. Stem Cell Inc
  • TikoMed AB
  • Symic Biomedical Inc
  • ReNeuron Group Plc
  • Pluristem Therapeutics Inc
  • Pharmicell Co Ltd
  • Nissan Chemical Industries Ltd
  • Neurofx Inc
  • Kasiak Research Pvt Ltd
  • Hemostemix Inc
  • Cynata Therapeutics Ltd
  • Caladrius Biosciences Inc
  • BiogenCell Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Critical Limb Ischemia Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Critical Limb Ischemia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Critical Limb Ischemia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Critical Limb Ischemia Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Critical Limb Ischemia Drug Market Dynamics
  1. 2.1 Critical Limb Ischemia Drug Industry Trends
  2. 2.2 Critical Limb Ischemia Drug Industry Drivers
  3. 2.3 Critical Limb Ischemia Drug Industry Opportunities and Challenges
  4. 2.4 Critical Limb Ischemia Drug Industry Restraints
3 Critical Limb Ischemia Drug Market by Manufacturers
  1. 3.1 Global Critical Limb Ischemia Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Critical Limb Ischemia Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Critical Limb Ischemia Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Critical Limb Ischemia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Critical Limb Ischemia Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Critical Limb Ischemia Drug Manufacturers, Product Type & Application
  7. 3.7 Global Critical Limb Ischemia Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Critical Limb Ischemia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Critical Limb Ischemia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Critical Limb Ischemia Drug Tier 1, Tier 2, and Tier 3
4 Critical Limb Ischemia Drug Market by Type
  1. 4.1 Critical Limb Ischemia Drug Type Introduction
  2. 4.1.1 NK-104 NP
  3. 4.1.2 NFx-101
  4. 4.1.3 JVS-100
  5. 4.1.4 HC-016
  6. 4.1.5 Others
  7. 4.2 Global Critical Limb Ischemia Drug Sales by Type
  8. 4.2.1 Global Critical Limb Ischemia Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Critical Limb Ischemia Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Critical Limb Ischemia Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Critical Limb Ischemia Drug Revenue by Type
  12. 4.3.1 Global Critical Limb Ischemia Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Critical Limb Ischemia Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Critical Limb Ischemia Drug Revenue Market Share by Type (2021-2032)
5 Critical Limb Ischemia Drug Market by Application
  1. 5.1 Critical Limb Ischemia Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Home Care
  4. 5.1.3 ASCs
  5. 5.2 Global Critical Limb Ischemia Drug Sales by Application
  6. 5.2.1 Global Critical Limb Ischemia Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Critical Limb Ischemia Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Critical Limb Ischemia Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Critical Limb Ischemia Drug Revenue by Application
  10. 5.3.1 Global Critical Limb Ischemia Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Critical Limb Ischemia Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Critical Limb Ischemia Drug Revenue Market Share by Application (2021-2032)
6 Global Critical Limb Ischemia Drug Sales by Region
  1. 6.1 Global Critical Limb Ischemia Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Critical Limb Ischemia Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Critical Limb Ischemia Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Critical Limb Ischemia Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Critical Limb Ischemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Critical Limb Ischemia Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Critical Limb Ischemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Critical Limb Ischemia Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Critical Limb Ischemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Critical Limb Ischemia Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Critical Limb Ischemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Critical Limb Ischemia Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Critical Limb Ischemia Drug Revenue by Region
  1. 7.1 Global Critical Limb Ischemia Drug Revenue by Region
  2. 7.1.1 Global Critical Limb Ischemia Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Critical Limb Ischemia Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Critical Limb Ischemia Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Critical Limb Ischemia Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Critical Limb Ischemia Drug Revenue (2021-2032)
  8. 7.2.2 North America Critical Limb Ischemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Critical Limb Ischemia Drug Revenue (2021-2032)
  11. 7.3.2 Europe Critical Limb Ischemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Critical Limb Ischemia Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Critical Limb Ischemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Critical Limb Ischemia Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Critical Limb Ischemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 U.S. Stem Cell Inc
  2. 8.1.1 U.S. Stem Cell Inc Company Information
  3. 8.1.2 U.S. Stem Cell Inc Business Overview
  4. 8.1.3 U.S. Stem Cell Inc Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 U.S. Stem Cell Inc Critical Limb Ischemia Drug Product Portfolio
  6. 8.1.5 U.S. Stem Cell Inc Recent Developments
  7. 8.2 TikoMed AB
  8. 8.2.1 TikoMed AB Company Information
  9. 8.2.2 TikoMed AB Business Overview
  10. 8.2.3 TikoMed AB Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 TikoMed AB Critical Limb Ischemia Drug Product Portfolio
  12. 8.2.5 TikoMed AB Recent Developments
  13. 8.3 Symic Biomedical Inc
  14. 8.3.1 Symic Biomedical Inc Company Information
  15. 8.3.2 Symic Biomedical Inc Business Overview
  16. 8.3.3 Symic Biomedical Inc Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Symic Biomedical Inc Critical Limb Ischemia Drug Product Portfolio
  18. 8.3.5 Symic Biomedical Inc Recent Developments
  19. 8.4 ReNeuron Group Plc
  20. 8.4.1 ReNeuron Group Plc Company Information
  21. 8.4.2 ReNeuron Group Plc Business Overview
  22. 8.4.3 ReNeuron Group Plc Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ReNeuron Group Plc Critical Limb Ischemia Drug Product Portfolio
  24. 8.4.5 ReNeuron Group Plc Recent Developments
  25. 8.5 Pluristem Therapeutics Inc
  26. 8.5.1 Pluristem Therapeutics Inc Company Information
  27. 8.5.2 Pluristem Therapeutics Inc Business Overview
  28. 8.5.3 Pluristem Therapeutics Inc Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pluristem Therapeutics Inc Critical Limb Ischemia Drug Product Portfolio
  30. 8.5.5 Pluristem Therapeutics Inc Recent Developments
  31. 8.6 Pharmicell Co Ltd
  32. 8.6.1 Pharmicell Co Ltd Company Information
  33. 8.6.2 Pharmicell Co Ltd Business Overview
  34. 8.6.3 Pharmicell Co Ltd Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pharmicell Co Ltd Critical Limb Ischemia Drug Product Portfolio
  36. 8.6.5 Pharmicell Co Ltd Recent Developments
  37. 8.7 Nissan Chemical Industries Ltd
  38. 8.7.1 Nissan Chemical Industries Ltd Company Information
  39. 8.7.2 Nissan Chemical Industries Ltd Business Overview
  40. 8.7.3 Nissan Chemical Industries Ltd Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Nissan Chemical Industries Ltd Critical Limb Ischemia Drug Product Portfolio
  42. 8.7.5 Nissan Chemical Industries Ltd Recent Developments
  43. 8.8 Neurofx Inc
  44. 8.8.1 Neurofx Inc Company Information
  45. 8.8.2 Neurofx Inc Business Overview
  46. 8.8.3 Neurofx Inc Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Neurofx Inc Critical Limb Ischemia Drug Product Portfolio
  48. 8.8.5 Neurofx Inc Recent Developments
  49. 8.9 Kasiak Research Pvt Ltd
  50. 8.9.1 Kasiak Research Pvt Ltd Company Information
  51. 8.9.2 Kasiak Research Pvt Ltd Business Overview
  52. 8.9.3 Kasiak Research Pvt Ltd Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Kasiak Research Pvt Ltd Critical Limb Ischemia Drug Product Portfolio
  54. 8.9.5 Kasiak Research Pvt Ltd Recent Developments
  55. 8.10 Hemostemix Inc
  56. 8.10.1 Hemostemix Inc Company Information
  57. 8.10.2 Hemostemix Inc Business Overview
  58. 8.10.3 Hemostemix Inc Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hemostemix Inc Critical Limb Ischemia Drug Product Portfolio
  60. 8.10.5 Hemostemix Inc Recent Developments
  61. 8.11 Cynata Therapeutics Ltd
  62. 8.11.1 Cynata Therapeutics Ltd Company Information
  63. 8.11.2 Cynata Therapeutics Ltd Business Overview
  64. 8.11.3 Cynata Therapeutics Ltd Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Cynata Therapeutics Ltd Critical Limb Ischemia Drug Product Portfolio
  66. 8.11.5 Cynata Therapeutics Ltd Recent Developments
  67. 8.12 Caladrius Biosciences Inc
  68. 8.12.1 Caladrius Biosciences Inc Company Information
  69. 8.12.2 Caladrius Biosciences Inc Business Overview
  70. 8.12.3 Caladrius Biosciences Inc Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Caladrius Biosciences Inc Critical Limb Ischemia Drug Product Portfolio
  72. 8.12.5 Caladrius Biosciences Inc Recent Developments
  73. 8.13 BiogenCell Ltd
  74. 8.13.1 BiogenCell Ltd Company Information
  75. 8.13.2 BiogenCell Ltd Business Overview
  76. 8.13.3 BiogenCell Ltd Critical Limb Ischemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 BiogenCell Ltd Critical Limb Ischemia Drug Product Portfolio
  78. 8.13.5 BiogenCell Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Critical Limb Ischemia Drug Value Chain Analysis
  2. 9.1.1 Critical Limb Ischemia Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Critical Limb Ischemia Drug Production Mode & Process
  6. 9.2 Critical Limb Ischemia Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Critical Limb Ischemia Drug Distributors
  9. 9.2.3 Critical Limb Ischemia Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst